Nipah virus infections therapeutic - Collaborations Pharmaceuticals
Latest Information Update: 09 Mar 2022
At a glance
- Originator Collaborations Pharmaceuticals
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Nipah virus infections
Most Recent Events
- 11 Feb 2022 Nipah virus infections therapeutic - Collaborations Pharmaceuticals is available for licensing as of 09 Feb 2022. https://www.collaborationspharma.com/how-we-collaborate
- 07 Feb 2022 Collaborations Pharmaceuticals has patent pending for Nipah virus infections before February 2022 (Collaborations Pharmaceuticals pipeline, February 2022)
- 07 Feb 2022 Preclinical trials in Nipah virus infections in USA (unspecified route) before February 2022 (Collaborations Pharmaceuticals pipeline, February 2022)